New device combo for liver chemotherapy shows promise in small trial
NCT ID NCT03693807
First seen Jun 27, 2026 ยท Last updated Jun 27, 2026
Summary
This study tested whether a Medtronic pump and Codman catheter can safely deliver chemotherapy directly to the liver in 35 people with colorectal cancer or bile duct cancer that spread to the liver. The main goal was to check safety, including liver side effects and need for stent replacements. This approach aims to control the disease, not cure it.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHOLANGIOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Basking Ridge
Basking Ridge, New Jersey, 07920, United States
-
Memorial Sloan Kettering Bergen
Montvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Memorial Sloan Kettering Commack
Commack, New York, 11725, United States
-
Memorial Sloan Kettering Monmouth
Middletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Nassau
Uniondale, New York, 11553, United States
-
Memorial Sloan Kettering Westchester
Harrison, New York, 10604, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we predict who will survive a bowel surgery leak?
- Can a Two-Drug attack shrink Hard-to-Treat colorectal tumors?
- Can a new drug ST316 shrink Hard-to-Treat tumors?
- A mobile app aims to turn health awareness into action โ a trial puts it to the test
- Can a walking routine alter cancer biomarkers? new trial investigates
- Web tool aims to empower rare cancer patients in genomic choices